Συναλλαγές Akero Therapeutics Inc - AKRO CFD

Akero Therapeutics Inc. (NASDAQ: AKRO) is a clinical-stage biopharmaceutical company focused on metabolic disease, with lead candidate efruxifermin (EFX) targeting NASH (nonalcoholic steatohepatitis). EFX is a fibroblast growth factor analog aiming to improve liver fibrosis and metabolic biomarkers. Akero’s trials have shown promising efficacy in early and mid-stage studies. The company provides investors with high-upside, high-risk exposure to one of the most competitive and high-value arenas in liver disease therapeutics.